Alimera Sciences, Inc. (NASDAQ:ALIM) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus price target of $4.00 for the company and are forecasting that the company will post ($0.03) EPS for the current quarter, according to Zacks. Zacks has also assigned Alimera Sciences an industry rank of 110 out of 265 based on the ratings given to related companies.
ALIM has been the topic of a number of recent research reports. Cowen and Company set a $3.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Tuesday, July 25th. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Finally, ValuEngine lowered shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th.
WARNING: “Alimera Sciences, Inc. (ALIM) Given Average Recommendation of “Strong Buy” by Brokerages” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/11/17/alimera-sciences-inc-alim-given-average-recommendation-of-strong-buy-by-brokerages.html.
Shares of Alimera Sciences (NASDAQ:ALIM) traded up $0.03 on Tuesday, hitting $1.25. 56,411 shares of the stock traded hands, compared to its average volume of 385,360. Alimera Sciences has a 1-year low of $1.04 and a 1-year high of $1.72. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84.
Several hedge funds have recently added to or reduced their stakes in ALIM. KCG Holdings Inc. increased its stake in shares of Alimera Sciences by 127.0% during the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 43,977 shares during the period. JW Asset Management LLC increased its stake in Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after purchasing an additional 130,000 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 35,200 shares during the last quarter. Finally, Stonepine Capital Management LLC increased its stake in Alimera Sciences by 158.2% in the third quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock valued at $644,000 after purchasing an additional 292,399 shares during the last quarter. Hedge funds and other institutional investors own 36.82% of the company’s stock.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.